chapter
The CHEK2 kinase functions in the DNA damage response pathway and, activated by ATM phosphorylates a variety of targets such as CDC25A/C, BRCA1 and p53. 1 Both truncating and some missense mutations in CHEK2 confer an increased breast cancer risk. Besides rare CHEK2 germline mutations, five founder mutations in CHEK2 have been identified with a variable prevalence in different populations. 2 The p.S428F mutation has a prevalence of 1.37% in the Ashkenazi Jewish population, p.I157T is most prevalent in Slavic populations (~5.0%), IVS+2G>A has been found in German and Polish populations (~0.3%), the del5395 in the Polish population, and CHEK2*1100delC with highest prevalence in Northern Europe. 2 The CHEK2*1100delC mutation results in a frameshift leading to a premature termination at codon 381. In the Netherlands the prevalence in the general population is 1.1%, 2.5% in unselected breast cancer cases and up to 4.9% in familial breast cancer cases. 3, 4 The populationbased breast cancer risk for a female CHEK2*1100delC carrier is consistently associated with odds ratio's between 1.5-3.0, corresponding to an estimated lifetime risk for breast cancer of approximately 20-25%.
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Although arguably influenced by ascertainment biases, publications have shown that female heterozygous CHEK2*1100delC carriers from a familial breast cancer setting have a higher lifetime breast cancer risk of 37%. 6, 7 Since females from western populations have an average lifetime risk of ~10%, this suggests that these females have a 3-fold increased breast cancer risk. This increased risk in a familial setting is most likely explained by a polygenic model in which other genetic risk factors present in these families contribute to the individual risk of these heterozygous cases. 6 Clinical utility of CHEK2*1100delC mutation testing is currently under debate. 2, 8, 9 We were interested whether homozygous female CHEK2*1100delC carriers have a higher cancer risk than heterozygous carriers. Since the prevalence of the CHEK2*1100delC allele is high in the Netherlands we are in the unique position to address this question. We then tested all available siblings (blood DNA or DNA from paraffin embedded material when deceased) of the 8 homozygous cases for the presence of CHEK2*1100delC homozygosity (for pedigrees see Figure 1 ). Of the total of 26 individuals tested in the generation concerned, we identified a total of 12 homozygous individuals (two males, 10 females, including our initial eight probands), and 12
heterozygous individuals (four males, eight females). All 10 female homozygotes had breast cancer; 7/10 had multiple primary tumors; four had bilateral breast cancer and four were additionally affected with colon cancer, ovarian cancer, uterine cancer or melanoma respectively (Table 1) . Of note, no homozygosity was found in any of the six unaffected females. One homozygous male had a thymoma at age 47 and the other homozygous male was cancer free at age 54 years.
In the proband generation 12 heterozygous CHEK2*1100delC carriers were Chapter 7 | CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women 116 males and five females) were not available for testing (six from one family, family 4). Table 1 shows the age of onset and histology of the breast cancer tumors in homozygous females. Median age of diagnosis of (first) breast cancer for the homozygous females was 47 years old (average age 44 years).
Of the 12 available tumors, 11 were grade 2-3 invasive ductal carcinoma. Nine out of 12 (75%) breast cancers were estrogen (ER) positive and eight progesterone (PR)
positive tumors, confirming the predominantly hormone positive tumors observed in heterozygote carriers of the CHEK2*1100delC mutation (Table 1) . 12 Remarkably, allele in these families.
In previous studies, homozygosity for the CHEK2*1100delC allele was once described in a Dutch male with colorectal cancer at age 52 and in a patient from German/Welsh descent who was bilaterally affected with breast cancer at age 47 and 61 and had an uterine sarcoma at age 58. 5, 13 In an independent bilateral breast cancer study we enrolled one additional family with homozygosity of the CHEK2*1100delC mutation and identified one homozygous female with bilateral breast cancer age 50 and 56 (both ER/PR positive, HER2 negative), and colon cancer at age 59; and two homozygous males of whom one died of colon cancer at age 32. These cases match well with our findings reported here. It is remarkable that colon cancer thus far has been described (present study combined with literature and our additional family) in four of the 17 homozygous individuals, with ages of onset of 32, 43, 59
and 52 years. Publications variably showed a higher prevalence of heterozygosity for the CHEK2*1100delC mutation in colorectal cohorts. 14, 15 Systematic studies are needed to evaluate the association between colorectal cancer or other cancers and CHEK2*1100delC homozygosity.
This is the first paper to describe the incidence of homozygosity for the CHEK2*1100delC in a large familial non-BRCA1/2 breast cancer cohort. 
Appendix Statistical Analysis

In this appendix we describe the estimation of genotype relative risks for breast cancer, the construnction of confidence intervals for these relative risks and a statistical test for testing the alternative hypothesis whether the breast cancer risk of homozygous females for the CHEK2*1100delC allele is more than two times the breast cancer risk of heterozygous females with the CHEK2*1100delC allele in familial breast cancer families. We first introduce some notation.
Notation
Denote the genotype frequencies among "familial breast cancer cases'' as
, with a the CHEK2*1100delC allele and A the wild type allele. We assume that the allele frequencies in the total population are in Hardy-Weinberg equilibrium (HWE) and it is therefore sufficient to introduce only notation for the allele frequencies and not the genotype frequencies; under the HWE-assumption the genotype frequencies can be written in terms of the allele frequencies. Denote the a and A allele frequencies in the total population as a q and A q , respectively. To estimate the genotype relative risks for breast cancer and to test the alternative hypo-thesis as stated above two 
Estimation of the Genotype Relative Risk (GRR)
By Bayes' rule and under the assumption of HWE in the total population the genotype relative risks can be written in terms of the parameters just defined: 
Test for relative risk
In the following we describe how to test the alternative hypothesis that the breast cancer risk for homozygous females is at least two times the risk for heterozygous females in familial breast cancer families; so we test the hypotheses The p-value is found by maximizing the sum of probabilities with respect to and a q . We found a p-value of 0.044. 
Construction of 95% confidence intervals for GRR
